8-KOther Events

QUEST DIAGNOSTICS INC 8-K Report, Corporate Update (Sep 5, 2013)

Filed September 5, 2013For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) announced on September 5, 2013, its entry into an accelerated share repurchase (ASR) agreement with Morgan Stanley to repurchase approximately $350 million of its common stock. This move is a significant component of the company's ongoing common stock repurchase program and signals management's confidence in the company's valuation and future prospects. The ASR agreement involves an initial payment of $350 million by Quest Diagnostics, with an initial delivery of 4,672,117 shares on the same day of the filing. The final number of shares repurchased will be determined by the volume-weighted average price during a specified period, with potential adjustments and provisions for additional share delivery or cash payments at settlement. This transaction is expected to conclude by the end of the fourth quarter of 2013.

Key Highlights

  • 1Quest Diagnostics entered into an accelerated share repurchase (ASR) agreement for approximately $350 million.
  • 2The ASR agreement is part of the company's existing common stock repurchase program.
  • 3An initial payment of $350 million will be made to Morgan Stanley.
  • 4Quest Diagnostics will receive an initial 4,672,117 shares of common stock on September 5, 2013.
  • 5The final number of shares repurchased will be based on the volume-weighted average price during a repurchase period, subject to discounts and adjustments.
  • 6The transaction is expected to be completed in the fourth quarter of 2013.
  • 7The ASR agreement includes customary provisions for adjustments, acceleration, and termination.

Frequently Asked Questions

An accelerated share repurchase (ASR) agreement is a contract where a company buys back its own shares from an investment bank (in this case, Morgan Stanley). The company usually pays a lump sum upfront, receives a portion of the shares immediately, and the final number of shares repurchased is determined later based on market prices over a set period.

Companies typically repurchase their stock when they believe the shares are undervalued and as a way to return capital to shareholders. It can also signal management's confidence in the company's financial health and future growth prospects.

The final number of shares will be based on the average of the daily volume-weighted average price per share of Quest Diagnostics' common stock during a specified repurchase period, less a discount. There are also provisions for potential adjustments, additional share deliveries, or cash payments at the final settlement.

This $350 million repurchase will reduce the number of outstanding shares, which can potentially increase earnings per share (EPS) if net income remains stable or grows. It also represents a significant outflow of cash, reducing the company's cash reserves.